Italy· 041393012
IMUNOCARE
A imiquimod product containing imiquimod, registered in Italy by DIFA COOPER S.P.A., on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against AIFA (Italy) on
Informational only — not a medical device.
Where it is registered
Imiquimod is registered in 16 of 19 countries.
Countries holding a registration under ATC D06BB10 (imiquimod), each read from that country’s own register.
- This record: Italy, from AIFA (Italy)
- 10 of them publish a price we can compare per daily dose
Imiquimod · ATC D06BB10
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
AIFA (Italy)- Active substance
- Imiquimod
- Manufacturer
- DIFA COOPER S.P.A.
- Country
- Italy (IT)
- ATC code
- D06BB10
- ATC class
- Imiquimod
- Reimbursed
- Yes
- Source register
- AIFA (Italy)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- aic0413930125% CREMA 12 BUSTINE DA 250 MGEUR 55.89
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
74 interactions on record for imiquimod.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Imiquimod · interactions on record
74 records
- 1 severe
- 3 moderate
- 70 info
Most severe, free to view
- Aminolevulinic acidL01XD04severe
- Porfimer sodiumL01XD01moderate
- MethoxsalenL01XD10moderate
- VerteporfinS01LA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Imiquimod in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesImiquimodOceanside Pharmacueticals
- United KingdomAldara 5% cream 250mg sachetsViatris UK Healthcare Ltd
- FinlandAldaraAbacus Medicine A/S
- SpainALDARA 5% CREMAViatris Healthcare Limited
- CzechiaALDARAVIATRIS HEALTHCARE LIMITED, Dublin
- SwitzerlandAldara
- CanadaALDARA PBAUSCH HEALTH, CANADA INC.
- FranceALDARA 5 %, crèmeVIATRIS HEALTHCARE (IRLANDE)
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Austria · Imikeraderm
- Cyprus · Modiwart
- Germany · Aksunim, Imikeraderm
- Spain · Imikeraderm, Imunocare
- United Kingdom (Northern Ireland) · Bascellex
- Greece · Modiwart, Quimodia
- Iceland · Aldara, Zyclara
- Liechtenstein · Aldara, Zyclara
- Netherlands · Bascellex
- Norway · Aldara, Bascellex
- Poland · Imikeraderm
- Portugal · Imicare
- Sweden · Bascellex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AIFA (Italy). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3f12d444-cac4-455a-aa32-337833a772c5 GET /v1/drugs/3f12d444-cac4-455a-aa32-337833a772c5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pack": "5% CREMA 12 BUSTINE DA 250 MG",
"source": "aifa",
"currency": "EUR",
"substance": "Imiquimod",
"reference_pack": "12 UNITA' 250 MG 5% - USO DERMATOLOGICO",
"public_price_eur": 55.89,
"ssn_reference_price_eur": 55.89
}See everything about imiquimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.